Disease Diagnosis TRIZ Cases

Combined PCT and MR-proADM thresholds improve infection severity assessment and support discharge, hospitalization, and antibiotic decisions.

Synaptic protein assays in exosomes and body fluids improve Alzheimer’s diagnosis accuracy without invasive brain tissue examination.

Blood levels of 2-aminoethyl dihydrogen phosphate and taurine enable earlier Alzheimer's detection and progression monitoring using routine clinical instruments.

Flow-cytometric blood testing of CD163, CD91, and MerTK improves preclinical Alzheimer's diagnosis and prognosis without invasive CSF sampling.

Marker profiling with CD82 and related surface markers identifies tumor-specific CD8+ T cells without prior antigen knowledge.

H3 isoform-specific binding distinguishes cell-free nucleosomes from dividing and non-dividing cells, improving tissue-origin analysis.

Combining GFAP and UCH-L1 measurements within 48 hours of head injury improves TBI assessment while reducing reliance on CT radiation.

Gender-stratified IgG cutoff values and selected food preparations improve migraine trigger food testing by reducing false positives and variability.

A single dried blood spot extraction enables simultaneous Lyso-Gb1 and Lyso-Gb3 detection, cutting processing steps for earlier LSD diagnosis.

Defined oxidized insulin peptide epitopes improve T1D and LADA diagnosis by enabling more reliable autoantibody and T cell detection.

Biomarkers and continuous temperature monitoring help predict CRS and ICANS early in CAR-T therapy, enabling timely intervention.

Single-cell SMR mass sensing captures immune response heterogeneity for more precise diagnosis and therapy monitoring.

GLUT1-positive plasma cell, lymphocyte, or blast proportions refine prognosis and help predict response to BCL-2 family modulators.

Magnetic bead capture and fluorescent tau assays detect ultra-low blood biomarker levels to improve brain injury prognosis and treatment planning.

Automated capillary electrophoresis isolates THBS1 plasma complexes to improve early breast cancer detection over noisy ELISA and manual blotting.

Circulating MMP, TIMP, and FGF protein panels help flag pulmonary vascular inadequacy before Stage 2 palliation in SVHD.

Endothelial dysfunction biomarkers help predict CRS and ICANS risk in IECT, enabling patient stratification and targeted monitoring.

EPA ethyl ester with statin therapy lowers cardiovascular event risk in atrial fibrillation patients while balancing triglycerides and arrhythmia risk.

Directly bonding biomolecule probes to epoxy resins removes pre-functionalization, cutting assay variability, time, and cost.

A weighted OA proteomic risk score stratifies AA and total joint replacement risk while helping assess NGF antagonist or NSAID response.

Measuring marker proteins in blood IgA immune complexes enables non-invasive IgA nephropathy assessment without renal biopsy.

A gold nanoparticle lateral flow strip detects serum CC16 in minutes, enabling affordable early silicosis screening without complex lab tests.

Profiles secreted proteins from individual stimulated cells in microchambers to assess CAR T safety, efficacy, and functional heterogeneity.

Stimulated PBMC acidification profiles enable non-invasive early lung cancer detection with higher specificity than LDCT or standard liquid biopsy.

Light scatter analysis of NNRBCs, combined with MDW and WBC, improves sepsis differentiation when standard tests lack specificity.

Multiple cytokine patterns and antibody assays enable more reliable fibromyalgia diagnosis and clearer differentiation from autoimmune pain disorders.

Direct SMR measurement of live cells avoids overnight culturing and enables precise mass accumulation rate analysis from small samples.

MRS tracks 3.15 and 3.19 ppm breast tissue signals to estimate cancer risk non-invasively from MMA-linked spectral changes.

Urine and stool metabolite profiling differentiates Crohn's disease from ulcerative colitis without repeat invasive endoscopy.

Single-domain anti-CAIX antibodies improve tumor-targeting specificity and affinity while lowering production complexity and cost.

A seven-protein blood biomarker panel improves early colorectal cancer and advanced adenoma staging with higher sensitivity and specificity.

MR-proADM cut-off levels help identify high-risk polytrauma patients early, supporting faster decisions on sepsis and other complications.

Detecting non-benign KIDINS220 variants in body fluid helps identify obese patients at elevated ESRD risk and guide earlier kidney treatment.

Multiple corticoid metabolites in feces, water, and post-mortem samples enable non-invasive fish stress assessment across acute and long-term periods.

Antigen probe arrays profile IgG and IgM brain-antigen reactivity to deliver faster, more objective brain injury diagnosis and reduce unnecessary imaging.

Flow cytometry of neutrophil mitochondrial membrane potential enables early diabetes risk assessment in people with normal blood glucose.

Measuring NLRP1, ASC, and caspase-1 in cerebrospinal fluid enables earlier CNS injury severity assessment and prognosis.

A TrkB.T1-targeting antibody enables broader cancer detection with one conserved isoform marker, reducing reliance on multiple tumor-specific markers.

Extracapsular synovial fluid detection with CT, MRI, ultrasound, or antibody binding enables earlier diagnosis before radiographic joint damage appears.

CSF-derived anti-Vimentin IgG enables earlier, highly specific VIMA diagnosis through a recombinant-plasmid-based detection kit.

Uses curated food preparations and IgG signal comparison with gender-stratified references to identify foods linked to ADD/ADHD symptoms.

Albumin-referenced NMR biomarker ratios in dry blood improve disease risk prediction when fingertip samples suffer dilution and variability.

CNN analysis of stained tumor cells creates repeatable single-cell ADC scores to predict response to B7-H4 antibody-drug conjugate therapy.

Clusterin and Fibronectin 1 in urine replace invasive kidney biopsy for CKD risk stratification, progression tracking, and treatment monitoring.

A plant-based litter uses natural pH-sensitive color changes in urine clumps to flag abnormal animal urine while avoiding irritating synthetic components.

Extracellular vesicle isolation with size exclusion chromatography enables rapid, sensitive detection of pathological alpha-synuclein before symptoms appear.

Low-limit blood tau detection enables more reliable brain injury prognosis and treatment decisions when biomarker levels are too low for standard assays.

Cell-surface CB2 on transfected mammalian cells enables antibodies that recognize native receptor structure and track agonist-induced internalization.

Solid-phase porcine membrane and antigen assays detect IgG and IgM titers quickly enough to stratify xenograft rejection risk.

Color-coded microspheres and control beads enable cost-effective, high-throughput plasma and serum quantification of six Alzheimer biomarkers.